Ryanodine receptor 2 mutations in catecholaminergic polymorphic ventricular tachycardia: From molecular mechanisms to precision medicine

Figure 2 Precision medicine approach to catecholaminergic polymorphic ventricular tachycardia management. Comprehensive precision medicine framework for catecholaminergic polymorphic ventricular tachycardia management incorporating genomic analysis, functional validation using patient-specific models, biomarker assessment, and personalized therapeutic selection. The approach enables mutation-specific risk stratification and targeted therapy selection based on individual patient characteristics. hiPSC: Human induced pluripotent stem cell; ICD: Implantable cardioverter defibrillator; SCD: Sudden cardiac death.